approval
saveDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 2 initiationNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)Apr 29, 2026 · 164d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalFeb 12, 2026 · 240d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 27, 2026 · 256d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 19, 2025 · 325d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 6, 2025 · 338d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJul 30, 2024 · 802d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 2, 2022 · 1438d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 21, 2022 · 1723d ago
same company · ±60 days · 6
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 19, 2025
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalNov 7, 2025
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 7, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 6, 2025
- approvalustekinumab: STELARA (USTEKINUMAB) — FDA approvalNov 3, 2025
- approvalSIMPONI (GOLIMUMAB) — FDA approvalOct 22, 2025
🐶 often sniffed alongside
top 8- drugdaratumumab31 co-mentions · 16 sources
- drugdaratumumab + Gene Therapy31 co-mentions · 16 sources
- drugDARZALEX FASPRO30 co-mentions · 15 sources
- tagApproval30 co-mentions · 15 sources
- companyJanssen Biotech Inc15 co-mentions · 15 sources
- tagOncology2 co-mentions · 1 sources
- tagMultiple Myeloma2 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that